Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $21.07 +2.43%
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Twilio (TWLO) PT Raised to $320 at Tigress Financial Partners
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
